Book a Meeting

Non-Fucosylated Anti-Human ADAM28 (211-12) Therapeutic Antibody (CAT#: BioBet-520ZP) Datasheet

Target
ADAM28
Isotype
IgG
Description
ADCC-Enhanced anti-ADAM28 (211-12) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ADAM28 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ADAM28
Full Name
ADAM metallopeptidase domain 28
Background
This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The protein encoded by this gene is a lymphocyte-expressed ADAM protein. This gene is present in a gene cluster with other members of the ADAM family on chromosome 8. Alternative splicing results in multiple transcript variants.
Alternative Names
ADAM28; ADAM metallopeptidase domain 28; MDCL; MDC-L; eMDCII; ADAM 28; eMDC II; disintegrin and metalloproteinase domain-containing protein 28; metalloproteinase-like, disintegrin-like, and cysteine-rich protein-L; epididymal metalloproteinase-like, disintegrin-like, and cysteine-rich protein II; epididymial metalloproteinase-like, disintegrin-like, and cysteine-rich protein II
Gene ID
10863
UniProt ID
P78536
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with ADAM28 include Hyperostosis Cranialis Interna and Laurence-Moon Syndrome.
Function
It may play a role in the adhesion and proteolytic events that occur during the migration of lymphocytes, and it may also play a role in the shedding of the outer domain of target proteins on the surface of lymphocytes (such as FASL and CD40L). It may be related to sperm maturation.
Post-translational modifications
Pro-domain removal and maturation may be, at least in part, autocatalytic.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
211-12
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced anti-ADAM28 (211-12) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human ADAM28 (297-2F3) Therapeutic Antibody (CAT#: BioBet-522ZP)
Non-Fucosylated Anti-Human ADAM28 (211-14) Therapeutic Antibody (CAT#: BioBet-521ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany